ArticleAnnals of hematology2025
Spontaneous remission of iMCD-TAFRO: a case report.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Idiopathic multicentric Castleman disease (iMCD)- TAFRO (thrombocytopenia, ascites, fever, reticulin fibrosis and organomegaly) is a clinically severe situation characterized by cytokine storms that are potentially fatal, necessitating prompt and decisive medical intervention. The International Castleman's Disease Collaborative Network (CDCN) prioritizes the combination of long-term siltuximab and high-dose steroids as the preferred therapeutic option for iMCD-TAFRO. Here, we report a rare case of spontaneous remission in iMCD-TAFRO. In this case, the patient diagnosed with iMCD-TAFRO experienced alleviation of clinical symptoms and normalization of laboratory test results without undergoing any etiological treatment. This case sheds new light on the therapeutic strategies for iMCD-TAFRO. Following the stabilization of the onset cytokine storm, a detailed evaluation of the patient's condition should be performed to determine the need for continuous medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.